1. The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer
- Author
-
Huang WS, Nie WW, Zhang WW, Wang YR, Zhu A, and Guan XX
- Subjects
Thioredoxin ,Androgen Receptor ,Cyclin D1 ,Breast Cancer ,Immunohistochemistry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Weisun Huang,1 Weiwei Nie,1 Wenwen Zhang,2 Yanru Wang,1 Aiyu Zhu,1 Xiaoxiang Guan1,2 1Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China Background: The ER signaling pathway plays a critical role in breast cancer. ER signaling pathway-related proteins, such as TRX, AR, and cyclin D1, may have an important function in breast cancer. However, the ways that they influence breast cancer development and progression are still unclear.Patients and methods: A total of 101 Chinese female patients diagnosed with invasive ductal breast adenocarcinoma were retrospectively enrolled in the study. The expression levels of TRX, AR, and cyclin D1 were detected by immunohistochemistry and analyzed via correlation with clinicopathological characteristics and the expression status of ER, PR, and HER2.Results: The expression status of TRX, AR, and cyclin D1 was not associated with the patient’s age, menopausal status, tumor size, or histological differentiation (P>0.05), but was positively correlated with ER and PR (P
- Published
- 2016